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===================

Members of the *Streptomyces* genus of Gram-positive filamentous bacteria produce diverse secondary metabolites, including two-thirds of clinical antibiotics ([@B1]). *Streptomyces* genomes have been shown to contain a rich repertoire of small-molecule-encoding biosynthetic loci ([@B2]). A high proportion of sequenced *Streptomyces* strains encode the biosynthesis of polycyclic tetramate macrolactams (PTMs) ([@B3]). *Streptomyces* sp. strain JV178 was isolated from a Connecticut (USA) garden soil sample during a screen to discover new PTM compounds ([@B4]). We have sequenced its genome to further understand clifednamide-type PTM biogenesis.

Strain JV178 was grown in Trypticase soy broth supplemented with 0.6% glycine at 28°C. Genomic DNA was extracted by phenol-chloroform extraction as described elsewhere ([@B5]). Sequencing was performed on a MiSeq platform (2 × 301-bp reads \[Illumina, Inc., San Diego, CA, USA\]) on a paired-end library prepared using a high-throughput library preparation kit (Kapa Biosystems). Adapter sequences and low-quality reads (quality score \< 0.05) were removed using CLC Genomics Workbench (CLC Bio-Qiagen, Aarhus, Denmark). The trimmed reads totaled 3,064 Mb, corresponding to approximately 287-fold coverage. *De novo* genome assembly was performed in CLC Genomics Workbench, and resulting contigs having less than 200 bp or 3× average coverage were discarded. The resulting draft genome contains 10,650,097 bp in 759 contigs (*N*~50~, 540,451 bp), with a G+C content of 71.0%. Gene prediction and annotation by the Rapid Annotations using Subsystems Technology version 2.0 pipeline ([@B6], [@B7]) predicted 9,045 protein coding sequences and 126 RNA genes.

Automated secondary metabolism analysis using antiSMASH version 4.0 ([@B8]) and PRISM version 3.0 ([@B9]) predicted 39 biosynthetic gene clusters. Six of these matched known clusters for concanamycin ([@B10]), coronafacic acid ([@B11]), marineosins ([@B12]), melanin, ectoine, and anticapsin ([@B13]). Using this sequence, the clifednamide biosynthetic cluster was also found ([@B14]), along with clusters predicted to encode five terpenes, three polyketides, three nonribosomal peptides, eight hybrid polyketide/nonribosomal peptides, four siderophores, five lantipeptides, a single lasso peptide, and three bacteriocins. Multilocus sequence alignment using *atpD*, *gyrB*, *recA*, *rpoB*, and *trpB* concatenates ([@B15]) identified the closest sequenced relative of strain JV178 as *Streptomyces torulosus* strain NRRL B-3889, consistent with prior 16s rRNA gene analysis ([@B3]). These results place this strain in the *S. scabiei* clade ([@B16]), which contains several plant-associated *Streptomyces* species, including the potato pathogen *S. scabiei* 87.22 ([@B17]). While we failed to detect homologs of known pathogenicity loci, such as *txtAB* ([@B18]), eight genes were predicted to encode the plant-growth hormone auxin. The absence of recognizable pathogenicity loci and the predicted ability to produce the plant modulators concanamycin ([@B10]), coronafacic acid ([@B11]), and auxin suggest a plant-associated but nonpathogenic lifestyle. These observations suggest potential roles for the clifednamides, whose targets are still unknown.
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The draft genome sequence of *Streptomyces* sp. strain JV178 was deposited in DDBJ/ENA/GenBank under the accession number [PEKU00000000](http://www.ncbi.nlm.nih.gov/nuccore/PEKU00000000). The version described in this paper is the first version, PEKU01000000.
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